ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting

    Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome   

    Maria Ester Simeira Fonseca1, Michelle Lopes2, Christiane Pereira Gouvea3 and Danieli Andrade4, 1Rheumatology, University of São Paulo, São Paulo, Brazil, 2Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 3Hematology, University of São Paulo, São Paulo, Brazil, 4Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY

    Background/Purpose:  Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…
  • Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting

    Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model

    Maria Gabriella Raimondo1,2, Charis Pericleous3, Anna Radziszewska4,5, Maria Orietta Borghi6,7, Silvia S. Pierangeli8, Pier Luigi Meroni6,9, Ian Giles3, Anisur Rahman3 and Yiannis Ioannou3,10, 1Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 2Centre for Rheumatology Research, UCL Division of Medicine, University College London, London, United Kingdom, 3Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, 4The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 5The Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, 6Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 7Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 8Rheumatology/Internal Medicine, University of Texas Medical Branch, Galveston, TX, 9Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Cusano Milanino (mi), Italy, 10Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom

    Background/Purpose:  β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…
  • Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting

    Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors

    Maria Gerosa1,2, Paola Adele Lonati3, Tania Ubiali1, Martina Cornalba1, Maria Orietta Borghi1,4 and Pier Luigi Meroni1,2,5, 1Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 2Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, 3Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Jamaica, 4Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 5Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy

    Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
  • Abstract Number: 2183 • 2015 ACR/ARHP Annual Meeting

    Clinical and Epidemiological Correlates of the Adjusted Global Anti-Phospholipid Syndrome Score in a Large Cohort of Chinese APS Patients

    Yu Zuo1, Chun Li2, David R. Karp3 and Zhanguo Li2, 1Rheumatology, UT Southwestern Medical Center, Dallas, TX, 2Peking University People's Hospital, Beijing, China, 3UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: It is well known that anti-phospholipid antibodies (aPL) are associated with an increased risk of arterial and venous thrombosis and pregnancy loss/morbidity. However, anticoagulation…
  • Abstract Number: 2184 • 2015 ACR/ARHP Annual Meeting

    Non-Criteria Clinical Manifestations in Antiphospholipid Syndrome: Clinical Behavior and Association with Damage Accrual

    Gabriela Hernandez-Molina1, Cindy Maldonado-Garcia1 and Antonio R. Cabral2, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 2Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico

    Background/Purpose: The relevance of non-criteria clinical manifestations of antiphospholipid syndrome (APS) has been less studied than its thrombotic and obstetric features. The aim of this…
  • Abstract Number: 2186 • 2015 ACR/ARHP Annual Meeting

    The Role of Hydroxychloroquine Treatment on Pregnancy Outcome in Women with Antiphospholipid Antibodies

    Savino Sciascia1, Beverely J Hunt2, Eva Talavera-Garcia3, Gloria Lliso3, Munther Khamashta3 and Mª Jose Cuadrado4, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Thrombosis & Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, 3Louise Coote Lupus Unit, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, London, United Kingdom, 4Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom

    Background/Purpose: With good management, around 70% of pregnant women with Antiphospholipid Syndrome (APS) will deliver a viable live infant.However, current management does not prevent all…
  • Abstract Number: 2192 • 2015 ACR/ARHP Annual Meeting

    Increased Risk of Thrombocytopenia Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    YU PEI CHOCK1, DENIS WAHL2 and STEPHANE ZUILY3, 1KENT MEMORIAL HOSPITAL, WARWICK, RI, 2CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, 3CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France

    Background/Purpose : Thrombocytopenia is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our objective was…
  • Abstract Number: 2195 • 2015 ACR/ARHP Annual Meeting

    Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study

    Francesca Dall'Ara1, Mara Taraborelli2, Rossella Reggia1, Micaela Fredi2, Maria Gerosa3, Laura Massaro4, Ariela Hoxha5, Marta Tonello5, Patrice Cacoub6, Nathalie Costedoat-Chalumeau7, Franco Franceschini2, Pier Luigi Meroni8, Jean Charles Piette6, Amelia Ruffatti5, Guido Valesini4 and Angela Tincani1, 1Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 3Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, 4Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, 5Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, 6Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, 7Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 8Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy

    Background/Purpose: Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients (pt) are still very limited.The objectives of this work was to assess the…
  • Abstract Number: 2199 • 2015 ACR/ARHP Annual Meeting

    in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial

    Chary Lopez-Pedrera1, Maria Ángeles Aguirre Zamorano1, Francisco Velasco2, Patricia Ruiz-Limon1, Nuria Barbarroja1, Yolanda Jiménez Gómez1, Maria Carmen Abalos-Aguilera1, Pedro Segui3, Eduardo Collantes-Estevez1, Lucia Fernandez-del Rio4, Jose Antonio Gonzalez-Reyes4, Jose Manuel Villalba4, Mª Jose Cuadrado5 and Carlos Perez-Sanchez1, 1IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, 2Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, 3IMIBIC-Reina Sofia University Hospital, Radiology Unit, Cordoba, Spain, 4Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, 5Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom

    Background/Purpose: To investigate the beneficial effects of in vivoubiquinol (Q, reduced form of CoQ10) supplementation on athero-thrombosis prevention in APS patients, through the implementation of…
  • Abstract Number: 2201 • 2015 ACR/ARHP Annual Meeting

    Triple Positivity of Antiphospholipid Antibody As the Main Thrombotic Factor in a Long-Term Follow-up Study of 98 Asymptomatic Apl-Positive Carriers

    Cécile Yelnik1,2, Elodie Drumez3, Sylvain Dubucquoi2,4,5, Vincent Sobanski1,2,4, Hélène Maillard1,6, Alain Duhamel3, David Launay1,2,4, Eric Hachulla1,2,4, Pierre-Yves Hatron1,2 and Marc Lambert1,2,4, 1Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, 2Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, 3CERIM, Université Lille Nord de France, Lille, France, 4LIRIC, INSERM UMR 995, Lille, France, 5Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, 6Faculté de Médecine Henri Warembourg, Université Lille Nord de France, lille, France

    Background/Purpose: There is limited data regarding the long-term risk of developing a first-time thrombotic event and prophylactic benefits of aspirin use in asymptomatic aPL-positive carriers.…
  • Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting

    Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis

    Krishan Gupta1, Manish Rathi2, Navin Pattanashetti3, Ritambhra Nada4 and Aman Sharma5, 1Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 3Internal Medicine, Junior Resident, Chandigarh, India, 4Histopathology, Professor, Chandigarh, India, 5Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…
  • Abstract Number: 2865 • 2014 ACR/ARHP Annual Meeting

    The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin

    Bahar Artim-Esen1, Natalia Smoktunowicz2, Vera M. Ripoll3, Charis Pericleous4, Rachel Chambers2, Ian Mackie5, David Isenberg6, Anisur Rahman7, Yiannis Ioannou6 and Ian Giles4, 1Department of Internal Medicine, Division of Rheumatology, Rheumatology Division, Department of Internal Medicine, Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey, 2Rayne Institute, 1st floor, Respiratory Research Unit, University College London, London, United Kingdom, 3Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, 4Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 5Haemostasis Research Unit, 1st Floor, 51 Chenies Mews, Haemostasis Research Unit, University College London, London, United Kingdom, 6Centre for Rheumatology Research, University College Hospital London, London, United Kingdom, 7Centre for Rheumatology Research, University College London, London, United Kingdom

    Background/Purpose Recently we showed that FXa reactive IgG in patients with the antiphospholipid syndrome (APS) displayed higher avidity binding to FXa and had greater functional…
  • Abstract Number: 2866 • 2014 ACR/ARHP Annual Meeting

    External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß2-Glycoprotein I. a Prospective Multicentre Cohort Study

    Stephane Zuily1, Bas De Laat2, Veronique Regnault3, Pierre Kaminsky4, Hilde Kelchtermans5, Zakera Shums6, Roger Albesa7, Gary L Norman6, Philip de Groot8, Anne-Christine Rat9, Jacques Ninet10, Nadine Magy-Bertrand11, Jean-Louis Pasquali12, Marc Lambert13, Bernard Lorcerie14, Thomas Lecompte15, Francis Guillemin16 and Denis Wahl17, 1CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, 2Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, 3Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, 4Internal Medicine, CHU Nancy, Vandoeuvre, France, 5Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, 6INOVA Diagnostics, San Diego, CA, 7Research, INOVA Diagnostics, San Diego, CA, 8Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, 9University Paris Descartes, EA 4360 APEMAC, University of Lorraine, Nancy, France, 10Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 11Bensançon University Hospital, Besançon, France, 12Service de Medecine Interne, Nouvel Hospital Civil, Strasbourg Cedex, France, 13Lille University Hospital, Lille, France, 14Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, 15Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, 16INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 17Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France

    Background/Purpose: Our objectives were 1- to perform an external validation of the Global Anti-Phospholipid Syndrome Score (GAPSS) and 2- to compare prognostic significances of GAPPS…
  • Abstract Number: 2867 • 2014 ACR/ARHP Annual Meeting

    Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps:  a New Mechanism of Thrombosis in the Antiphospholipid Syndrome

    Srilakshmi Yalavarthi1, Levi F. Mazza1, Alexandra E. Morris1, Carlos Núñez-Álvarez2, Diego Hernández2, Paula L. Bockenstedt3, Antonio R. Cabral4 and Jason S. Knight1, 1Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 3Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

    Background/Purpose:  Antiphospholipid antibodies (aPL), especially those targeting beta-2-glycoprotein I, are known to activate endothelial cells, monocytes, and platelets, with prothrombotic implications.  However, the interaction of…
  • Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting

    Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels

    Markos Patsouras1, Marina Sikara2, Athanasios G. Tzioufas2 and Panayiotis Vlachoyiannopoulos2, 1PATHOPHYSIOLOGY DEPARTMENT, UNIVERSITY OF ATHENS, School of Medicine, National University of Athens, Athens, Greece, 2Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

    Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology